Heppt MV, et al. – This paper strived to yield a comprehensive overview with regard to the efficacy, safety, and tolerability of immune checkpoint blockade (ICB) in patients with uveal melanoma (UM). The findings disclosed that UM was little responsive to ipilimumab, irrespective of dosage schemes. Sound randomized clinical trials were necessitated to determine the efficacy of combined ICB in patients with UM.